Related Experiment Video
Updated: Aug 5, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
A Modified Delphi Consensus on Optimal Pharmacological Management of Insomnia: Insights from a Malaysian Perspective
Ng Chong Guan1, Ahmad Hatim Sulaiman1, Nor Hazlin Talib2
1Department of Psychological Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Abstract:
Insomnia represents a significant risk factor for impaired daytime functioning and a range of chronic health conditions and has emerged as a growing public health concern in Malaysia. The absence of standardised local guidelines complicates treatment decision-making. This consensus aimed to develop pharmacological treatment recommendations for insomnia in Malaysia using a modified Delphi approach. An eight-member expert panel comprising specialists in sleep medicine, psychiatry, neurology, and pharmacology reviewed high-level evidence on the neurobiology, diagnosis, and treatment of insomnia. A 31-item consensus statement survey addressing the definition, diagnosis, and pharmacological management of insomnia was conducted, with agreement evaluated using a five-point Likert scale. The consensus recommendations were finalised after two Delphi rounds and a final vote, with at least 75% agreement required for each statement. Consensus statements highlighted the need for tailored treatment strategies in Malaysia that combine nonpharmacological and pharmacological interventions. Insomnia was recognised as a chronic condition diagnosed primarily using subjective criteria, with sleep diaries and questionnaires recommended as assessment tools. Benzodiazepines, Z-class drugs, and dual orexin receptor agonists (DORAs) were found to be effective; however, concerns regarding long-term safety and dependency were noted. DORAs demonstrated promise in managing both sleep onset and maintenance, with lemborexant highlighted as a promising pharmacological option. The meeting emphasised the importance of individualised treatment plans and careful risk assessment, particularly for older adults, and provided practical recommendations for the management of insomnia. The integration of Cognitive Behavioural Therapy for Insomnia with pharmacotherapy was strongly advocated. These consensus statements offer a practical foundation for the development of future national guidelines to enhance insomnia care in Malaysia's primary care settings.
Related Concept Videos
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Insomnia
Multiple factors contribute...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
CNS Depressants: Barbiturates and Benzodiazepines
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
